Segmented Metformin Tablet with pH Buffer for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for treating Type 2 diabetes often face challenges in achieving optimal dosing ratios and stability of DPP-4 inhibitors and SGLT-2 inhibitors when combined with metformin, particularly in maintaining the chemical stability and uniformity of these drugs in extended and immediate release formulations.
Innovation Solution
A fixed-dose combination of a DPP-4 inhibitor (linagliptin) and/or SGLT-2 inhibitor (Compound A) with metformin in extended release form, utilizing a specific coating process and formulation that includes an inner extended release core of metformin and an outer immediate release coating, ensuring chemical stability, uniformity, and controlled release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a fixed-dose combination of DPP-4 inhibitor and metformin is formulated, then effective glycemic control is achieved, but chemical stability and content uniformity become difficult to maintain
Solution Approach 1:
The tablet is divided into two distinct layers: an immediate-release layer containing the DPP-4 inhibitor (linagliptin) and an extended-release layer containing metformin. This segmentation prevents direct interaction between the two drugs that could compromise chemical stability, while maintaining their individual release profiles for effective glycemic control.
Solution Approach 2:
A pH-adjusting agent (such as magnesium oxide, calcium carbonate, or sodium bicarbonate) is introduced as an intermediary substance between the DPP-4 inhibitor and metformin. This intermediary maintains an alkaline environment that stabilizes the DPP-4 inhibitor against degradation by metformin's acidic properties, ensuring chemical stability throughout storage and dissolution.
2Duration of action of moving object
If extended release formulation is used for metformin, then sustained drug release is achieved, but content uniformity and dissolution characteristics become difficult to control
Solution Approach 1:
The tablet is divided into two distinct layers: an immediate-release layer containing the DPP-4 inhibitor (linagliptin) and an extended-release layer containing metformin. This segmentation allows each layer to be optimized independently for its release profile, ensuring content uniformity within each layer while achieving the desired extended release duration for metformin.
Solution Approach 2:
The dissolution characteristics of metformin are controlled by adjusting parameters such as polymer type (e.g., HPMC with different viscosity grades), polymer-to-drug ratio, and granulation method. These parameter changes enable precise control over the extended release profile while maintaining content uniformity through standardized manufacturing processes.
3Adaptability or versatility
If a broad range of drug substance ratios is accommodated, then versatility in dosing is achieved, but manufacturing complexity increases
Solution Approach 1:
The segmented biconvex tablet design with immediate-release and extended-release layers allows independent adjustment of drug ratios in each layer. This segmentation provides dosing flexibility for various DPP-4 inhibitor to metformin ratios without requiring complete reformulation, as each layer can be manufactured separately and combined in different proportions.
Solution Approach 2:
The formulation uses universal excipients and manufacturing processes (such as wet granulation and fluid bed drying) that can accommodate a broad range of drug substance ratios. The pH-adjusting agent serves multiple functions: stabilizing the DPP-4 inhibitor, controlling dissolution rate, and maintaining content uniformity, thereby reducing formulation complexity despite dosing flexibility requirements.
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.